Market Research Logo

Traumatic Brain Injury - Pipeline Review, H2 2015

Traumatic Brain Injury - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Traumatic Brain Injury - Pipeline Review, H2 2015’, provides an overview of the Traumatic Brain Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Traumatic Brain Injury and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Traumatic Brain Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Traumatic Brain Injury pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Traumatic Brain Injury Overview
Therapeutics Development
Pipeline Products for Traumatic Brain Injury - Overview
Pipeline Products for Traumatic Brain Injury - Comparative Analysis
Traumatic Brain Injury - Therapeutics under Development by Companies
Traumatic Brain Injury - Therapeutics under Investigation by Universities/Institutes
Traumatic Brain Injury - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Traumatic Brain Injury - Products under Development by Companies
Traumatic Brain Injury - Products under Investigation by Universities/Institutes
Traumatic Brain Injury - Companies Involved in Therapeutics Development
Adamas Pharmaceuticals, Inc.
ALSP, Inc.
Amarantus Bioscience Holdings, Inc.
Athersys, Inc.
BHR Pharma, LLC
Cognosci, Inc.
Euroscreen S.A.
Grupo Ferrer Internacional, S.A.
International Stem Cell Corporation
Io Therapeutics, Inc.
Ischemix
Karyopharm Therapeutics, Inc.
Kyorin Pharmaceutical Co., Ltd.
Levolta Pharmaceuticals, Inc.
Lixte Biotechnology Holdings, Inc.
Lpath, Inc.
MandalMed, Inc.
Mapreg S.A.S.
Mnemosyne Pharmaceuticals, Inc.
Neuralstem, Inc.
Neuren Pharmaceuticals Limited
NeuroHealing Pharmaceuticals Inc.
NeuroNascent, Inc.
Neuronax SAS
NeuroVive Pharmaceutical AB
Omeros Corporation
PharmatrophiX, Inc.
Phylogica Limited
Prevacus, Inc.
PsychoGenics, Inc.
QR Pharma, Inc.
RAPID Pharmaceuticals AG
RegeneRx Biopharmaceuticals, Inc.
Remedy Pharmaceuticals, Inc.
Sage Therapeutics
SanBio, Inc.
STATegics, Inc.
Tetra Discovery Partners LLC
VG Life Sciences, Inc.
Traumatic Brain Injury - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
2-DG - Drug Profile
ALP-496 - Drug Profile
amantadine hydrochloride ER - Drug Profile
AMRS-001 - Drug Profile
apomorphine hydrochloride - Drug Profile
AST-002 - Drug Profile
AVL-8168 - Drug Profile
Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile
CHEC-7 - Drug Profile
CHEC-9 - Drug Profile
CMX-2043 - Drug Profile
CNB-001 - Drug Profile
COG-1410 - Drug Profile
cyclosporine - Drug Profile
dexamethasone acetate + melatonin - Drug Profile
EPO-Variant - Drug Profile
ESN-502 - Drug Profile
felbamate - Drug Profile
FIB-117 - Drug Profile
glyburide - Drug Profile
HBI-002 - Drug Profile
HBI-137 - Drug Profile
HBN-1 - Drug Profile
HBN-2 - Drug Profile
HPI-201 - Drug Profile
ibudilast - Drug Profile
ICCN-100 - Drug Profile
IRX-4204 - Drug Profile
ISC-hpNSC - Drug Profile
JM-4 - Drug Profile
KPT-350 - Drug Profile
LB-201 - Drug Profile
LB-205 - Drug Profile
LM11A-31 - Drug Profile
Lpathomab - Drug Profile
MAP-4343 - Drug Profile
MultiStem - Drug Profile
ND-478 - Drug Profile
NNI-370 - Drug Profile
NNZ-2591 - Drug Profile
NSI-189 - Drug Profile
NSI-566 - Drug Profile
NVP-019 - Drug Profile
NVX-428 - Drug Profile
NX-210 - Drug Profile
PGI-02776 - Drug Profile
Posiphen - Drug Profile
progesterone - Drug Profile
PRV-002 - Drug Profile
PYC-35 - Drug Profile
PYC-36 - Drug Profile
PYC-38 - Drug Profile
PYC-98 - Drug Profile
R-503 - Drug Profile
RAP-701 - Drug Profile
RGN-352 - Drug Profile
SB-623 - Drug Profile
sepranolone - Drug Profile
Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile
Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile
Small Molecule to Inhibit Amyloid Beta Peptide for Traumatic Brain Injury and Alzheimer’s Disease - Drug Profile
Small Molecules for Stroke and Traumatic Brain Injury - Drug Profile
Small Molecules to Activate P2Y Receptor for Stroke and Traumatic Brain Injury - Drug Profile
Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System - Drug Profile
Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Drug Profile
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile
Stem Cell Therapy for CNS Disorders - Drug Profile
STSE-15 - Drug Profile
T-094 - Drug Profile
TBI-121 - Drug Profile
TBI-122 - Drug Profile
TBI-123 - Drug Profile
trofinetide - Drug Profile
UH-0113 - Drug Profile
UH-0213 - Drug Profile
VG-1177 - Drug Profile
VitalHeme - Drug Profile
VOLT-02 - Drug Profile
Traumatic Brain Injury - Recent Pipeline Updates
Traumatic Brain Injury - Dormant Projects
Traumatic Brain Injury - Discontinued Products
Traumatic Brain Injury - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Traumatic Brain Injury, H2 2015
Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2015
Traumatic Brain Injury - Pipeline by Adamas Pharmaceuticals, Inc., H2 2015
Traumatic Brain Injury - Pipeline by ALSP, Inc., H2 2015
Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015
Traumatic Brain Injury - Pipeline by Athersys, Inc., H2 2015
Traumatic Brain Injury - Pipeline by BHR Pharma, LLC, H2 2015
Traumatic Brain Injury - Pipeline by Cognosci, Inc., H2 2015
Traumatic Brain Injury - Pipeline by Euroscreen S.A., H2 2015
Traumatic Brain Injury - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015
Traumatic Brain Injury - Pipeline by International Stem Cell Corporation, H2 2015
Traumatic Brain Injury - Pipeline by Io Therapeutics, Inc., H2 2015
Traumatic Brain Injury - Pipeline by Ischemix, H2 2015
Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals, Inc., H2 2015
Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015
Traumatic Brain Injury - Pipeline by Lpath, Inc., H2 2015
Traumatic Brain Injury - Pipeline by MandalMed, Inc., H2 2015
Traumatic Brain Injury - Pipeline by Mapreg S.A.S., H2 2015
Traumatic Brain Injury - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2015
Traumatic Brain Injury - Pipeline by Neuralstem, Inc., H2 2015
Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Limited, H2 2015
Traumatic Brain Injury - Pipeline by NeuroHealing Pharmaceuticals Inc., H2 2015
Traumatic Brain Injury - Pipeline by NeuroNascent, Inc., H2 2015
Traumatic Brain Injury - Pipeline by Neuronax SAS, H2 2015
Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H2 2015
Traumatic Brain Injury - Pipeline by Omeros Corporation, H2 2015
Traumatic Brain Injury - Pipeline by PharmatrophiX, Inc., H2 2015
Traumatic Brain Injury - Pipeline by Phylogica Limited, H2 2015
Traumatic Brain Injury - Pipeline by Prevacus, Inc., H2 2015
Traumatic Brain Injury - Pipeline by PsychoGenics, Inc., H2 2015
Traumatic Brain Injury - Pipeline by QR Pharma, Inc., H2 2015
Traumatic Brain Injury - Pipeline by RAPID Pharmaceuticals AG, H2 2015
Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2015
Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals, Inc., H2 2015
Traumatic Brain Injury - Pipeline by Sage Therapeutics, H2 2015
Traumatic Brain Injury - Pipeline by SanBio, Inc., H2 2015
Traumatic Brain Injury - Pipeline by STATegics, Inc., H2 2015
Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H2 2015
Traumatic Brain Injury - Pipeline by VG Life Sciences, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Traumatic Brain Injury Therapeutics - Recent Pipeline Updates, H2 2015
Traumatic Brain Injury - Dormant Projects, H2 2015
Traumatic Brain Injury - Dormant Projects (Contd..1), H2 2015
Traumatic Brain Injury - Dormant Projects (Contd..2), H2 2015
Traumatic Brain Injury - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Traumatic Brain Injury, H2 2015
Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report